Anticoagulation and Stroke

Area of Science:

• Neurology
• Cardiology
• Hematology

Background:

• The 2019 American Heart Association guidelines do not support emergent anticoagulation for acute ischemic stroke.
• Specific clinical scenarios warrant a re-evaluation of anticoagulation's role in ischemic stroke management.
• Understanding indications and contraindications for anticoagulation is crucial for patient outcomes.

Purpose of the Study:

• To analyze the indications for anticoagulation in specific acute ischemic stroke cases.
• To discuss secondary prevention strategies using anticoagulation.
• To address the challenges in timing anticoagulation restart after stroke or hemorrhagic transformation.

Main Methods:

• Review of current guidelines and clinical evidence regarding anticoagulation in ischemic stroke.
• Analysis of specific patient populations requiring anticoagulation.
• Discussion of factors influencing the decision to restart anticoagulation post-stroke.

Main Results:

• Anticoagulation may be indicated for ischemic stroke due to extracranial artery thrombus with artery-to-artery embolization.
• Indications include stroke from cervical artery dissection, catastrophic antiphospholipid syndrome (APS), and certain COVID-19 cases.
• Secondary prevention with anticoagulation is recommended for cardioembolic stroke, cervical artery dissection, cancer-associated stroke, and thrombophilia (e.g., APS).

Conclusions:

• Anticoagulation has defined roles in specific acute ischemic stroke scenarios and for secondary prevention.
• Restarting anticoagulation after stroke, particularly with hemorrhagic transformation, necessitates a delayed approach (minimum 2 weeks, ideally 4 weeks) due to high thromboembolic risk.